Jushu Biotech Secures Over RMB 100 Million in Pre-A Funding to Advance Industrialization of Synthetic Biology

VCBeat has learned that Jushu Biology recently announced the completion of its Pre-A financing round, raising over RMB 100 million. The round was co-led by Binhu State-owned Investment, Xi Venture Capital, and ZHONGSU CAPITAL, with existing investors Chengwei Capital and 3E Bioventures increasing their stakes. The company will focus on the application development and mass production of synthetic biology solutions for industrial implementation.

Jushu Biologics is a global leader in data-driven, custom design and construction of engineered cells. Leveraging whole-genome editing technology and ultra-high-throughput droplet microfluidics, the company has developed an ultra-high-throughput platform for engineered cell modification and protein production. It develops and manufactures multiple therapeutic proteins that meet top-tier international quality standards and has completed cell chassis engineering for several leading domestic enterprises. Committed to efficient and agile strain chassis optimization, Jushu Biologics develops and produces proteins of international quality, meeting market demand for high-quality, large-volume, and cost-effective protein products.

After years of accumulation, the company now possesses genome-scale gene editing technology, ultra-high-throughput droplet microfluidic screening technology, high-performance synthetic biosensing technology, proprietary recombinant protein construction strategies, and a whole-genome genotype-industrial phenotype association database.Core Technology. FeaturingUltra-high-throughput cell chassis engineering and screening, enhancing protein production efficiency to reduce costs, etc.Platform Advantages.